Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) FCF Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed FCF Margin for 6 consecutive years, with 166.05% as the latest value for Q1 2025.

  • On a quarterly basis, FCF Margin rose 21118.0% to 166.05% in Q1 2025 year-over-year; TTM through Sep 2025 was 674.57%, a 46721.0% decrease, with the full-year FY2024 number at 235.55%, up 1177.0% from a year prior.
  • FCF Margin was 166.05% for Q1 2025 at Whitehawk Therapeutics, up from 224.88% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 8802.5% in Q1 2021 to a low of 842.57% in Q1 2022.
  • A 5-year average of 400.65% and a median of 214.71% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -964507bps in 2022, then skyrocketed 47275bps in 2023.
  • Whitehawk Therapeutics' FCF Margin stood at 89.1% in 2021, then plummeted by -151bps to 223.72% in 2022, then skyrocketed by 50bps to 111.59% in 2023, then plummeted by -102bps to 224.88% in 2024, then grew by 26bps to 166.05% in 2025.
  • Per Business Quant, the three most recent readings for WHWK's FCF Margin are 166.05% (Q1 2025), 224.88% (Q4 2024), and 205.7% (Q3 2024).